(Q28220999)

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Aspirin and clopidogrel resistance: an emerging clinical entity

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Homocysteine lowering and cardiovascular events after acute myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Homocysteine lowering with folic acid and B vitamins in vascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Peripheral arterial disease detection, awareness, and treatment in primary care

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01767.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Mortality over four years in SHEP participants with a low ankle-arm index

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Effects of colestipol-niacin therapy on human femoral atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Beta-blockers in heart failure: are pharmacological differences clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Nebivolol: a review of its clinical and pharmacological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Ramipril: a review of its use in the prevention of cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Improving foot care for people with diabetes mellitus--a randomized controlled trial of an integrated care approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X

Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01767.X